BEYFORTUS

This brand name is authorized in United States. It is also authorized in Austria, Canada, Croatia, Estonia, France, Ireland, Italy, Lithuania, Romania, Spain.

Active ingredients

The drug BEYFORTUS contains one active pharmaceutical ingredient (API):

1	Nirsevimab UNII VRN8S9CW5V - NIRSEVIMAB
	Nirsevimab is a recombinant neutralising human IgG1ĸ long-acting monoclonal antibody to the prefusion conformation of the RSV F protein which has been modified with a triple amino acid substitution (YTE) in the Fc region to extend serum half-life. Nirsevimab inhibits the essential membrane fusion step in the viral entry process, neutralising the virus and blocking cell-to-cell fusion.
	Read more about Nirsevimab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
BEYFORTUS Solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J06BD08		J Antiinfectives for systemic use → J06 Immune sera and immunoglobulins → J06B Immunoglobulins → J06BD Antiviral monoclonal antibodies
Discover more medicines within J06BD08

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02537206, 02537214
EE	Ravimiamet	1893405, 1893427, 1893438, 1893449
ES	Centro de información online de medicamentos de la AEMPS	1221689001, 1221689004
FR	Base de données publique des médicaments	62438151, 65150617
IT	Agenzia del Farmaco	050403017, 050403029, 050403031, 050403043, 050403056, 050403068
LT	Valstybinė vaistų kontrolės tarnyba	1095796, 1095797, 1095798, 1095799, 1095800, 1095801
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W69258001, W69258002, W69258003, W69259001, W69259002, W69259003
US	FDA, National Drug Code	49281-574, 49281-575